MG
HUMA icon

Michael Gelband’s Humacyte HUMA Stock Holding History

Michael Gelband’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,081
Closed -$21K – 1749
2025
Q2 		$21K Sell
10,081
-141,773
-93% -$272K ﹤0.01% 1383
2025
Q1 		$259K Buy
+151,854
New +$570K ﹤0.01% 1258
2022
Q2 		– Sell
-105,525
Closed -$745K – 2146
2022
Q1 		$745K Buy
+105,525
New +$614K 0.01% 1318

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Michael Gelband's HUMA Position: Q3 2025 in Review

Michael Gelband sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 10,081 shares — an estimated $21K sold.

Michael Gelband first reported a position in HUMA in Q1 2022 and held it in 3 quarters. The position peaked at $745K in Q1 2022. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

  • Michael Gelband reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
  • Michael Gelband sold 10,081 Humacyte shares in Q3 2025, an estimated $21K.
  • Michael Gelband first reported a position in Humacyte in Q1 2022 and held it in 3 quarters.
  • Michael Gelband's Humacyte position peaked at $745K in Q1 2022.
  • 141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.